Logo image of NXGL

NEXGEL INC (NXGL) Stock Fundamental Analysis

NASDAQ:NXGL - Nasdaq - US65344E1073 - Common Stock - Currency: USD

2.21  +0.09 (+4.25%)

Premarket: 2.161 -0.05 (-2.22%)

Fundamental Rating

3

Overall NXGL gets a fundamental rating of 3 out of 10. We evaluated NXGL against 188 industry peers in the Health Care Equipment & Supplies industry. NXGL has a bad profitability rating. Also its financial health evaluation is rather negative. NXGL is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year NXGL has reported negative net income.
In the past year NXGL has reported a negative cash flow from operations.
In the past 5 years NXGL always reported negative net income.
In the past 5 years NXGL always reported negative operating cash flow.
NXGL Yearly Net Income VS EBIT VS OCF VS FCFNXGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -1M -2M -3M -4M

1.2 Ratios

The Return On Assets of NXGL (-29.87%) is comparable to the rest of the industry.
NXGL has a Return On Equity (-57.01%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -29.87%
ROE -57.01%
ROIC N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
NXGL Yearly ROA, ROE, ROICNXGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

1.3 Margins

With a Gross Margin value of 31.63%, NXGL is not doing good in the industry: 73.40% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of NXGL has grown nicely.
The Profit Margin and Operating Margin are not available for NXGL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 31.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
NXGL Yearly Profit, Operating, Gross MarginsNXGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

2

2. Health

2.1 Basic Checks

NXGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NXGL has been increased compared to 1 year ago.
NXGL has more shares outstanding than it did 5 years ago.
NXGL has a worse debt/assets ratio than last year.
NXGL Yearly Shares OutstandingNXGL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
NXGL Yearly Total Debt VS Total AssetsNXGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

NXGL has an Altman-Z score of -0.34. This is a bad value and indicates that NXGL is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -0.34, NXGL perfoms like the industry average, outperforming 40.96% of the companies in the same industry.
NXGL has a Debt/Equity ratio of 0.16. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.16, NXGL perfoms like the industry average, outperforming 54.79% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Altman-Z -0.34
ROIC/WACCN/A
WACC8.84%
NXGL Yearly LT Debt VS Equity VS FCFNXGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 5M 10M

2.3 Liquidity

NXGL has a Current Ratio of 2.07. This indicates that NXGL is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.07, NXGL is doing worse than 65.43% of the companies in the same industry.
A Quick Ratio of 1.36 indicates that NXGL should not have too much problems paying its short term obligations.
NXGL has a Quick ratio of 1.36. This is in the lower half of the industry: NXGL underperforms 67.02% of its industry peers.
Industry RankSector Rank
Current Ratio 2.07
Quick Ratio 1.36
NXGL Yearly Current Assets VS Current LiabilitesNXGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.47% over the past year.
The Revenue has grown by 112.47% in the past year. This is a very strong growth!
The Revenue has been growing by 64.56% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)9.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
Revenue 1Y (TTM)112.47%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%121.64%

3.2 Future

Based on estimates for the next years, NXGL will show a very strong growth in Earnings Per Share. The EPS will grow by 49.41% on average per year.
The Revenue is expected to grow by 37.17% on average over the next years. This is a very strong growth
EPS Next Y87.76%
EPS Next 2Y72.01%
EPS Next 3Y61.64%
EPS Next 5Y49.41%
Revenue Next Year50.22%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y37.17%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NXGL Yearly Revenue VS EstimatesNXGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 20M 40M 60M
NXGL Yearly EPS VS EstimatesNXGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for NXGL. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 4.61, the valuation of NXGL can be described as very cheap.
Compared to the rest of the industry, the Price/Forward Earnings ratio of NXGL indicates a rather cheap valuation: NXGL is cheaper than 98.40% of the companies listed in the same industry.
NXGL's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.13.
Industry RankSector Rank
PE N/A
Fwd PE 4.61
NXGL Price Earnings VS Forward Price EarningsNXGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NXGL Per share dataNXGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
NXGL's earnings are expected to grow with 61.64% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y72.01%
EPS Next 3Y61.64%

More info and screens

0

5. Dividend

5.1 Amount

NXGL does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NEXGEL INC

NASDAQ:NXGL (5/29/2025, 8:00:28 PM)

Premarket: 2.161 -0.05 (-2.22%)

2.21

+0.09 (+4.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)05-13 2025-05-13/amc
Earnings (Next)N/A N/A
Inst Owners6.05%
Inst Owner Change40.77%
Ins Owners19.15%
Ins Owner Change-1.97%
Market Cap16.91M
Analysts82.86
Price Target6.12 (176.92%)
Short Float %1.14%
Short Ratio1.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-7.84%
Min EPS beat(2)-7.84%
Max EPS beat(2)-7.84%
EPS beat(4)2
Avg EPS beat(4)2.51%
Min EPS beat(4)-7.84%
Max EPS beat(4)23.75%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.44%
Min Revenue beat(2)-0.36%
Max Revenue beat(2)1.24%
Revenue beat(4)3
Avg Revenue beat(4)1.05%
Min Revenue beat(4)-0.36%
Max Revenue beat(4)2.84%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-300%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0.63%
Revenue NY rev (3m)0.64%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 4.61
P/S 1.95
P/FCF N/A
P/OCF N/A
P/B 2.94
P/tB 4.43
EV/EBITDA N/A
EPS(TTM)-0.45
EYN/A
EPS(NY)0.48
Fwd EY21.69%
FCF(TTM)-0.56
FCFYN/A
OCF(TTM)-0.51
OCFYN/A
SpS1.14
BVpS0.75
TBVpS0.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.87%
ROE -57.01%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 31.63%
FCFM N/A
ROA(3y)-35.81%
ROA(5y)-46.56%
ROE(3y)-62.13%
ROE(5y)-690.12%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y266%
GM growth 5YN/A
F-Score4
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0.16
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 101.61%
Cap/Sales 5.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.07
Quick Ratio 1.36
Altman-Z -0.34
F-Score4
WACC8.84%
ROIC/WACCN/A
Cap/Depr(3y)166.83%
Cap/Depr(5y)273.19%
Cap/Sales(3y)9%
Cap/Sales(5y)18.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%35.71%
EPS Next Y87.76%
EPS Next 2Y72.01%
EPS Next 3Y61.64%
EPS Next 5Y49.41%
Revenue 1Y (TTM)112.47%
Revenue growth 3Y77.64%
Revenue growth 5Y64.56%
Sales Q2Q%121.64%
Revenue Next Year50.22%
Revenue Next 2Y46.25%
Revenue Next 3Y44.56%
Revenue Next 5Y37.17%
EBIT growth 1Y-2.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year88.89%
EBIT Next 3Y61.03%
EBIT Next 5YN/A
FCF growth 1Y-9.61%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-19.5%
OCF growth 3YN/A
OCF growth 5YN/A